View:
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
November 20, 2006
-----------------
A.P. Pharma, Inc.
------------------------------------------------------
(Exact name of registrant as specified in its charter)
000-16109
------------------------
(Commission File Number)
Delaware 94-2875566
- ----------------------------- ------------------
(State or other jurisdiction (I.R.S. Employer
of incorporation) Identification No.)
123 Saginaw Drive
Redwood City, CA 94063
---------------------------------------------------------
(Address of principal executive offices, with zip code)
(650) 366-2626
-----------------------------------------------------
(Registrant's telephone number, including area code)
N/A
-------------------------------------------------------------
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the
registrant under any of the following provisions (see General
Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02 Departure of Directors or Principal Officers; Election
of Directors; Appointment of Principal Officer
On November 20, 2006, the Board of Directors of A.P. Pharma, Inc.
(the "Company") accepted the resignation of Dennis L. Winger from
the Company's Board of Directors and the Audit Committee and the
Finance Committee of the Board of Directors. He was replaced on
the Audit Committee by Peter Riepenhausen.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the Registrant has duly caused this report to be signed
on its behalf by the undersigned hereunto duly authorized.
A.P. PHARMA, INC.
Date: November 20, 2006 By: /s/ Stephen C. Whiteford
------------------- -------------------------
Stephen C. Whiteford
Vice President, Finance and
Chief Financial Officer